Markers of GABA neurotransmission are altered in multiple regions of the neocortex in individuals with schizophrenia. Lower levels of glutamic acid decarboxylase 67 (GAD67) mRNA and protein, which is responsible for most cortical GABA synthesis, are accompanied by lower levels of GABA membrane transporter 1 (GAT1) mRNA. These alterations are thought to be most prominent in the parvalbumin (PV)-containing subclass of interneurons, which also contain lower levels of PV mRNA. Since GAT1 and PV each reduce the availability of GABA at postsynaptic receptors, lower levels of GAT1 and PV mRNAs have been hypothesized to represent compensatory responses to an upstream reduction in cortical GABA synthesis in schizophrenia. However, such cause-and-effect hypotheses cannot be directly tested in a human illness. Consequently, we used two mouse models with reduced GAD67 expression specifically in PV neurons (PV GAD67+/− ) or in all interneurons (GABA GAD67+/− ) and quantified GAD67, GAT1 and PV mRNA levels using methods identical to those employed in studies of schizophrenia. Cortical levels of PV or GAT1 mRNAs were not altered in PV GAD67+/− mice during postnatal development or in adulthood. Furthermore, cellular analyses confirmed the predicted reduction in GAD67 mRNA, but failed to show a deficit in PV mRNA in these animals. Levels of PV and GAT1 mRNAs were also unaltered in GABA GAD67+/− mice. Thus, mouse lines with cortical reductions in GAD67 mRNA that match or exceed those present in schizophrenia, and that differ in the developmental timing and cell type-specificity of the GAD67 deficit, failed to provide proof-of-concept evidence that lower PV and GAT1 expression in schizophrenia are a consequence of lower GAD67 expression. Together, these findings suggest that the correlated decrements in cortical GAD67, PV and GAT1 mRNAs in schizophrenia may be a common consequence of some other upstream factor.
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Introduction
Schizophrenia is associated with alterations in several markers of GABA neurotransmission in multiple cortical regions, including prefrontal, primary motor, primary visual, and anterior cingulate cortices (Akbarian and Huang, 2006; Benes and Berretta, 2001; Fung et al., 2010; Hashimoto et al., 2008) . Both mRNA (Akbarian et al., 1995; Duncan et al., 2010; Straub et al., 2007; Volk et al., 2000) and protein (Curley et al., 2011; Guidotti et al., 2000) levels of the 67 kDa isoform of glutamic acid decarboxylase (GAD67), the enzyme responsible for the majority of cortical GABA synthesis, are lower in the neocortex of subjects with schizophrenia. Levels of GABA membrane transporter 1 (GAT1) mRNA, which removes GABA from the extracellular space, are also lower in schizophrenia (Hashimoto et al., 2008; Ohnuma et al., 1999; Volk et al., 2001) . These deficits in GABA synthesis and reuptake appear to be most prominent in the fast-spiking, parvalbumin-(PV) containing subclass of interneurons that also contain lower levels of PV mRNA (Hashimoto et al., 2003) .
Through different mechanisms, PV and GAT1 can each reduce the amount of GABA available at postsynaptic receptors; therefore, lower expression of PV and GAT1 mRNAs in schizophrenia has been hypothesized to be a compensatory response to counteract insufficient GABA synthesis (Lewis et al., 2005) . PV is a slow Ca 2+ buffer that increases the rate at which residual Ca 2+ transients decay in GABA nerve terminals after neurotransmitter release (Collin et al., 2005; Muller et al., 2007) . Therefore, during repetitive firing, reductions in PV levels in schizophrenia would increase the amount of calcium available to facilitate neurotransmitter release, resulting in increased synaptic GABA levels (Lewis et al., 2005) . In fact, mice deficient in PV show enhanced GABA release from fast-spiking neurons (Collin et al., 2005; Vreugdenhil et al., 2003) . GAT1, one of four high-affinity Na + /Cl − transporters that take up extracellular GABA, is the most abundant membrane GABA transporter in the cortex (Conti et al., 1998) . Consistent with a role for GAT1 in removing extracellular GABA from the synaptic space, in the hippocampus of GAT1 KO mice 3
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